MN-TA-ASSOCIATES
10.10.2019 21:17:12 CEST | Business Wire | Press release
HelpSystems (“the Company”), a global provider of IT operations management, security and analytics solutions, today announced that leading private equity firms TA Associates and Charlesbank Capital Partners have signed a definitive agreement to become additional investors, enabling the Company to continue its path of global growth. The firms will join existing investors HGGC, management and employees. Financial terms of the transaction were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005765/en/
Founded in 1982, HelpSystems is a leading provider of systems and network management, business intelligence, and security and compliance solutions. The Company’s software and services monitor and automate processes, encrypt and secure data, and provide access to the information that large organizations need every day. HelpSystems maintains offices around the world with customers ranging from small businesses to Fortune 100 companies.
“HelpSystems has grown and transformed significantly over the past few years, expanding its cybersecurity business and enhancing its leading cross-platform, automation and secure data transfer products,” said Harry D. Taylor, a Managing Director at TA Associates who will join the HelpSystems Board of Directors. Michael M. Libert, a Senior Vice President at TA Associates who will also join the Board, added, “We have been impressed by the Company's strong reputation with its customers, as well as its vibrant corporate culture. We look forward to supporting their track record of organic growth, as well as inorganic growth as an acquirer of strategic companies.”
“We are excited to be investing in this terrific company and its deep and talented management team,” said Hiren V. Mankodi, a Managing Director at Charlesbank Capital Partners who will also join the Company’s Board of Directors. “HelpSystems is well-positioned for continued growth, and we look forward to building on its momentum and its broad suite of IT products and solutions for its expanding customer base.”
“Today marks an important milestone for HelpSystems as we continue to make significant strides in providing the highest quality products and service offerings to our dedicated global customer base,” said Kate Bolseth, Chief Executive Officer of HelpSystems. “Having the ability to bring aboard two highly talented, long-term and well-respected growth investors such as TA and Charlesbank, both of whom are fully aligned with and supportive of our business model, is truly a unique opportunity that we believe will accelerate our growth trajectory and help us expand into additional emerging and opportunistic markets. We are honored to welcome both of these firms to the HelpSystems family, and look forward to benefiting from their complementary array of resources and skills.”
“Our partnership with HGGC has helped us innovate and deliver a broader, stronger solution set to our customers,” said Jim Cassens, President of HelpSystems. “HelpSystems has doubled in size every few years, and we believe that there are significant opportunities to further broaden our portfolio for our more than 17,000 customers. With this additional investment from TA and Charlesbank, we will seek to carry on our well-known tradition of listening closely to customers and delivering exceptional software that is based on their requirements, as well as those of the industries they serve, and that also addresses their complex challenges.”
“We have been very pleased with our investment in HelpSystems, and we look forward to the addition of TA and Charlesbank as the HelpSystems team brings to market an effective approach to automate, optimize and secure systems that businesses rely on every day,” said John Block, a Partner at HGGC.
The transaction is expected to close in November 2019 pending customary regulatory approvals and closing conditions.
Kirkland & Ellis provided legal counsel to HelpSystems and HGGC. Goodwin Procter provided legal counsel to TA Associates while Ropes & Gray advised Charlesbank Capital Partners.
About HelpSystems
HelpSystems aligns IT and business goals to help organizations build a competitive edge. Our software and services monitor and automate processes, encrypt and secure data, and provide easy access to the information people need. More than 17,000 organizations around the world rely on HelpSystems to make IT lives easier and keep business running smoothly. Learn more at www.helpsystems.com
.
About TA Associates
TA Associates is one of the most experienced global growth private equity firms. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – TA invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 500 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $32.5 billion in capital since its founding in 1968 and is committing to new investments at the pace of over $2 billion per year. The firm’s more than 85 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA Associates can be found at www.ta.com
.
About Charlesbank Capital Partners
Based in Boston and New York, Charlesbank Capital Partners is a middle-market private equity investment firm managing more than $5 billion of capital. Charlesbank focuses on management led buyouts and growth capital financings and also engages in opportunistic credit and technology investments. The firm seeks to partner with strong management teams to build companies with sustainable competitive advantage and excellent prospects for growth. For more information, please visit www.charlesbank.com
.
About HGGC
HGGC is a leading middle-market private equity firm with $4.3 billion in cumulative capital commitments. Based in Palo Alto, Calif., HGGC is distinguished by its Advantaged Investing approach that enables the firm to source and acquire scalable businesses through partnerships with management teams, founders and sponsors who reinvest alongside HGGC, creating a strong alignment of interests. Over its history, HGGC has completed more than 140 platform investments, add-on acquisitions, recapitalizations and liquidity events with an aggregate transaction value of nearly $22 billion. More information, including a complete list of current and former portfolio companies is available at www.hggc.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005765/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
